Smoking cessation interventions for COPD: A review of the literature

Respiratory Care

Volumn 58, Issue 11, 2013, Pages 1955-1962

  Pires Yfantouda, Renata ^a   Absalom, Gareth ^b   Clemens, Felicity ^c  

^a CITY UNIVERSITY   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

COPD; Pharmacotherapy; Psychosocial interventions

Indexed keywords

AMFEBUTAMONE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE DURATION; DISEASE SEVERITY; HUMAN; INTERVENTION STUDY; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; SMOKING HABIT; SYSTEMATIC REVIEW;

COPD; PHARMACOTHERAPY; PSYCHOSOCIAL INTERVENTIONS;

HEALTH PROMOTION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SMOKING CESSATION;

EID: 84886288272     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01923     Document Type: Review

References (25)

1. World Health Organization. Chronic respiratory diseases: chronic obstructive pulmonary disease (COPD). http://www.who.int/respira tory/COPD/en. Accessed August 21, 2013.
2. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121(5 Suppl):121S-126S.
3. United Kingdom National Health Service. Chronic obstructive pulmonary disease: introduction. http://www.nhs.uk/Conditions/Chronicobstructive-pulmonary-disease/Pages/Introduction.aspx. Accessed August 21, 2013.
4. National Institute for Health and Clinical Excellence. Quick reference guide: chronic obstructive pulmonary disease: management of chronic pulmonary disease in adults in primary and secondary care. 2004. http://www.nice.org.uk/CG012quickrefguide. Accessed August 21, 2013.
5. Department of Health. NHS Stop Smoking Services: service and monitoring guidance 2009/10. London: The Stationery Office; 2009.
6. Jiménez-Ruiz CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C, Sobradillo V. Smoking characteristics. Differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001;119(5):1365-1370.
7. Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract 2002;52(475):132-134.
8. Hill K, Geist R, Goldstein RS, Lacasse Y. Anxiety and depression in end-stage COPD. Eur Respir J 2008;31(3):667-677.
9. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63(7):831-838.
10. Coventry PA, Gellatly JL. Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy. Br J Health Psychol 2008;13(3): 381-400.
11. Stage KB, Middelboe T, Stage TB, Sorensen CH. Depression in COPD: Management and quality of life considerations. Int J COPD 2006;(3):315-320.
12. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care 2008;177(1):19-26.
13. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89.
14. Wagena EJ, van der Meer RM, Ostelo RJWG, Jacobs JE, Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004;98(9):805-815.
15. Strassman R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomized trials. Eur Respir J 2009;34(3):634-640.
16. American Thoracic Society. COPD guidelines. http://www.thoracic. org/go/COPD. Accessed August 21, 2013.
17. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild AG. The Delphi list: a criteria list for quality assessment of random clinical trials for conduction systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51(12):1235-1241.
18. Christenhusz L, Pieterse M, Seydel E, van de Palen J. Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Educ Couns 2007; 66(2):162-166.
19. Willemse B, Lesman-Leegte I, Timens W, Postma D, ten Hacken N. High cessation rates of cigarette smoking in subjects with and without COPD. Chest 2005;128(5):3685-3687.
20. Sundblad BM, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res 2008;10(5):883-890.
21. Wilson JS, Fitzsimons D, Bradbury I, Elborn JS. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomized controlled trial. Int J Nurs Stud 2008;45(4):508-517.
22. Wagena EJ, de Graaf L, Chavannes NH, van Grootheest AC, van Schayck CP. [Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified]. J Ned Tijdschr Geneeskd 2001; 145(31):1489-1492. Article in Dutch.
23. Van der Meer RM, Wagena EJ, Ostelo RW, Jacobs JE, van Schayck CP. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003;(2):CD002999.
24. Velicer WF, Prochaska JO, Rossi JS, Snow MG. Assessing outcome in smoking cessation studies. Psychol Bull 1992;111(1):23-41.
25. Bittoun R. A combination nicotine replacement therapy (NRT) algorithm for hard-to-treat smokers. J Smok Cessat 2006;1(1):3-6.